Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines

Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines

Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) is the rate-limiting enzyme for the detoxification of fluoropyrimidines (FLs). Rs4294451 is a regulatory DPYD polymorphism that has recently been functionally characterized and associated with increased DPD expression in the liver. The...

Full description

Bibliographic Details
Main Authors: Elena De Mattia, Jerry Polesel, Lucia Scarabel, Erika Cecchin
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
DPYD
rs4294451
fluoropyrimidine
toxicity
colorectal cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1516375/full

Similar Items

Similar Items